10-Q · May 12, 2026
ProMIS Neurosciences (PMN) continues to experience significant losses, with a net loss of $8.24 million in Q1 2026, compared to $7.35 million in Q1 2025. The company has not generated any revenue and had negative cash…
Earnings analysis · 10-Q
PMN earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q text does not disclose revenue, EPS, margins, cash flow, segment results, or detailed balance-sheet figures, preventing a conventional quarter-over-quarter or year-over-year earnings assessment.…
Read full summary
The provided 10-Q text does not disclose revenue, EPS, margins, cash flow, segment results, or detailed balance-sheet figures, preventing a conventional quarter-over-quarter or year-over-year earnings assessment. Management characterizes the company as pre-revenue, expects continued losses, and states that working capital was approximately $49.5 million as of June 30, 2026 while substantial additional financing will be required. The principal signal is elevated liquidity and funding risk as clinical and development spending increases.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Working capital remains positive
Management reported working capital of approximately $49.5 million as of June 30, 2026, providing near-term funding for ongoing operations.
-
Disclosure controls effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes in internal control during the three months ended June 30, 2026.
-
Limited reported interest-rate exposure
A hypothetical 10% relative change in interest rates was not expected to have a material impact on the financial statements as of June 30, 2026.
What to watch
-
Continued losses and no revenue
The company identifies itself as a pre-revenue development-stage company and states that it has incurred losses since inception and anticipates continued losses for the foreseeable future.
-
Substantial financing need
The company had working capital of approximately $49.5 million as of June 30, 2026, but states that substantial additional funds will be required for research and development, clinical testing, regulatory approvals, manufacturing, and potential commercialization.
-
Rising and uncertain development costs
Management expects expenses to increase as it conducts ongoing and planned preclinical studies, existing and new clinical trials, and potential regulatory activities; the filing states that actual development and commercialization costs cannot be reasonably estimated.
Management's outlook
No quantitative financial guidance was disclosed in the provided 10-Q text. Management states that the company is pre-revenue, expects continued losses for the foreseeable future, and will require substantial additional funding.
Earlier filings 4
10-K · March 25, 2026
ProMIS (PMN) positions itself as a discovery-to-clinic biotech focused on antibody therapeutics that selectively target toxic, misfolded protein conformations using its proprietary EpiSelect platform. The company’s lead…
10-Q · November 12, 2025
ProMIS reported no revenue and a Q3 2025 net loss of $11,580,126 (EPS -$0.24) versus net income of $9,275,825 (EPS $0.31) in Q3 2024. Operating expenses rose sharply — total operating expenses were $11,750,432 in Q3…
10-Q · August 13, 2025
ProMIS reported a large increase in R&D and overall operating spending in Q2 2025, driving a wider net loss of $10,117,029 for the three months ended June 30, 2025 (six‑month loss $17,464,932). Cash declined to…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.